SERIAL MEASUREMENT OF EPSTEIN-BARR VIRAL LOAD IN PERIPHERAL BLOOD IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS DURING TREATMENT FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE1
- 1 December 1998
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 66 (12), 1641-1644
- https://doi.org/10.1097/00007890-199812270-00012
Abstract
Few data are available describing the natural history of the Epstein-Barr virus (EBV) viral load after the diagnosis of EBV-associated posttransplant lymphoproliferative disease (PTLD). Accordingly, we prospectively followed the EBV viral load after the diagnosis of EBV/PTLD in seven pediatric orthotopic liver transplant recipients.EBV viral loads were serially measured by quantitative competitive polymerase chain reaction of the peripheral blood from pediatric patients with PTLD and correlated with the clinical course of these children. Viral loads >200 genome copies/10(5) peripheral blood lymphocytes were considered consistent with an increased risk of PTLD. Viral loads 200 were considered evidence of virologic "rebound."The mean EBV viral load at the time of diagnosis of PTLD was 1029. All patients "cleared" their EBV viral load during the treatment of PTLD; patient and graft survival in this series was 100%. The mean time to clearance of EBV from the peripheral blood (18.8 days) was similar to the mean time to onset of first rejection (13.8 days). EBV viral load at the time of diagnosis of rejection after PTLD was always 200 was noted in five of seven patients a median of 3.5 months (range 2.3-13 months) after the diagnosis of EBV/PTLD. However, none of these children has had any evidence of PTLD recurrence.Clearance of the EBV viral load from the peripheral blood seems to correlate with restoration of the host's immune response as noted both by the regression of the PTLD and the onset of rejection. Late rebound of the EBV viral load is common and does not seem to predict disease recurrence.Keywords
This publication has 8 references indexed in Scilit:
- New strategies in the prevention and management of Epstein-Barr virus infection and posttransplant lymphoproliferative disease following solid organ transplantationCurrent Opinion in Organ Transplantation, 1998
- Recurrent Epstein-Barr virus-associated lesions in organ transplant recipientsHuman Pathology, 1996
- EPSTEIN-BARR VIRUS DNA IN PERIPHERAL BLOOD LEUKOCYTES OF PATIENTS WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASETransplantation, 1995
- Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative diseaseBritish Journal of Haematology, 1995
- Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipientsBlood, 1994
- Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative diseaseBlood, 1994
- EBV Gene Expression, EBNA Antibody Responses and EBV+Peripheral Blood Lymphocytes in Post-Transplant Lymphoproliferative DiseaseLeukemia & Lymphoma, 1994
- Expression of Epstein–Barr Virus–Encoded Small RNA (by the EBER-1 Gene) in Liver Specimens from Transplant Recipients with Post-Transplantation Lymphoproliferative DiseaseNew England Journal of Medicine, 1992